Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins - resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology / de Boer, Rudolf A; De Keulenaer, Gilles; Bauersachs, Johann; Brutsaert, Dirk; Cleland, John G; Diez, Javier; Du, Xiao-Jun; Ford, Paul; Heinzel, Frank R; Lipson, Kenneth E; Mcdonagh, Theresa; Lopez-Andres, Natalia; Lunde, Ida G; Lyon, Alexander R; Pollesello, Piero; Prasad, Sanjay K; Tocchetti, Carlo G; Mayr, Manuel; Sluijter, Joost P G; Thum, Thomas; Tschöpe, Carsten; Zannad, Faiez; Zimmermann, Wolfram-Hubertus; Ruschitzka, Frank; Filippatos, Gerasimos; Lindsey, Merry L; Maack, Christoph; Heymans, Stephane. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - (2019). [10.1002/ejhf.1406]

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

Tocchetti, Carlo G;Heymans, Stephane
2019

Abstract

Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins - resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.
2019
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology / de Boer, Rudolf A; De Keulenaer, Gilles; Bauersachs, Johann; Brutsaert, Dirk; Cleland, John G; Diez, Javier; Du, Xiao-Jun; Ford, Paul; Heinzel, Frank R; Lipson, Kenneth E; Mcdonagh, Theresa; Lopez-Andres, Natalia; Lunde, Ida G; Lyon, Alexander R; Pollesello, Piero; Prasad, Sanjay K; Tocchetti, Carlo G; Mayr, Manuel; Sluijter, Joost P G; Thum, Thomas; Tschöpe, Carsten; Zannad, Faiez; Zimmermann, Wolfram-Hubertus; Ruschitzka, Frank; Filippatos, Gerasimos; Lindsey, Merry L; Maack, Christoph; Heymans, Stephane. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - (2019). [10.1002/ejhf.1406]
File in questo prodotto:
File Dimensione Formato  
Boer_et_al-2019-European_Journal_of_Heart_Failure.pdf

solo utenti autorizzati

Licenza: Accesso privato/ristretto
Dimensione 2.63 MB
Formato Adobe PDF
2.63 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/733749
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 177
  • ???jsp.display-item.citation.isi??? 155
social impact